-

01:30:45 AM

ADXS Stock News

ADXS - Advaxis, Inc.

01/11/22 8:00 AM

Nasdaq : ADXS

clinical trial

Advaxis Presents Updated Clinical Data from Ongoing Phase 1/2 Trial of ADXS-503 in NSCLC and Upcoming Milestones

Updated data show a second partial response in Part B Overall response rate of 15.4% and disease control rate of 46% in Part B with durable clinical benefit in patients with prior disease progression Preliminary data show disease control rate of 67% in first 3 patients in Part C, with ADXS-503

RHEA-AI

positive

12/22/21 4:05 PM

Nasdaq : ADXS

Advaxis Announces Acceptance for Trading on the OTCQX

Advaxis, Inc. (OTCQX: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced that the Company has satisfied the requirements for trading of the Company’s

RHEA-AI

neutral

12/17/21 8:00 AM

Nasdaq : ADXS

Advaxis to Continue to Explore Additional Options to Maximize Stockholder Value

Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology

RHEA-AI

very positive

12/09/21 8:00 AM

Nasdaq : ADXS

Advaxis Issues Letter to Stockholders Regarding Recent Special Meeting Results

RHEA-AI

positive

11/24/21 8:00 AM

Nasdaq : ADXS

Advaxis Issues Letter and Second Video Message to Stockholders Regarding Upcoming Special Meeting

Company releases video message highlighting the need for all proposals to pass in order to consummate the proposed Biosight transaction Advaxis urges stockholders to vote “FOR” all of the proposals at the special meeting in order to best position the company to build long term stockholder value

RHEA-AI

neutral

11/22/21 8:00 AM

Nasdaq : ADXS

acquisition

Nasdaq Grants Advaxis, Inc. an Extension to December 20, 2021, to Complete Merger Transaction with Biosight, Ltd. and Satisfy Initial Listing Requirements

Advaxis, Inc. (Nasdaq: ADXS) (“Advaxis” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of proprietary Lm-based antigen delivery products, announced that it has received a letter

RHEA-AI

positive

11/19/21 8:00 AM

Nasdaq : ADXS

Advaxis, Inc. Issues Letter to Stockholders

Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the

RHEA-AI

positive

11/18/21 8:00 AM

Nasdaq : ADXS

acquisition

Leading Independent Proxy Advisory Firm Glass Lewis Joins ISS in Recommending Advaxis Stockholders Vote “FOR” Proposed Merger with Biosight

Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today

RHEA-AI

neutral

11/04/21 8:00 AM

Nasdaq : ADXS

Advaxis Issues Letter and Video Message to Stockholders Regarding Upcoming Special Meeting

Company releases video message highlighting strategic rationale and benefits of proposed Biosight transaction for Advaxis stockholders Advaxis urges stockholders to vote “FOR” all of the proposals at the special meeting in order to best position the company to build long term stockholder value

RHEA-AI

neutral

11/03/21 8:00 AM

Nasdaq : ADXS

acquisition

Leading Independent Proxy Advisory Firm ISS Recommends Advaxis Stockholders Vote “FOR” the Merger with Biosight

Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products today announced that leading proxy advisory firm Institutional Shareholder Services Inc.

RHEA-AI

neutral

ADXS Data:

IndustryPharmaceutical Preparation Manufacturing
Websitewww.advaxis.com
CeoKenneth Berlin
Security nameAdvaxis, Inc.
Issue typecs
SectorManufacturing
Sic code2834
Employees18
Tags
- Health Technology
- Biotechnology
- Manufacturing
- Pharmaceutical Preparation Manufacturing
Address305 College Rd E
StateNew Jersey
CityPrinceton
Zip08540-6608
CountryUS
Phone17325451590

ADXS Description:

Advaxis, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of proprietary Lm-based antigen delivery products. These immunotherapies are based on a platform technology that utilizes live attenuated Listeria monocytogenes (Lm) bioengineered to secrete antigen/adjuvant fusion proteins. These Lm-based strains are believed to be a significant advancement in immunotherapy as they integrate multiple functions into a single immunotherapy and are designed to access and direct antigen presenting cells to stimulate anti-tumor T cell immunity, activate the immune system with the equivalent of multiple adjuvants, and simultaneously reduce tumor protection in the tumor microenvironment to enable T cells to eliminate tumors.